Pancreatic Cancer Research

ResearcherFudan UniversityActive in the last 2 years

Zeen Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7018-2813; OpenAlex author ID A5090889182. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2021: 1 paper · 2022: 7 papers · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 10

  1. MUC15 loss promotes perineural invasion in pancreatic cancer by activating the IGF1R/STAT3/NGF pathway. Co-author DOI 10.1016/j.canlet.2026.218362↗
  2. Elevated SREBP1 accelerates the initiation and growth of pancreatic cancer by targeting SOX9. Co-author DOI 10.1186/s13062-025-00595-1↗
  3. NNK from tobacco smoking enhances pancreatic cancer cell stemness and chemoresistance by creating a β2AR-Akt feedback loop that activates autophagy. Co-author DOI 10.1002/1878-0261.13230↗
  4. Piezo1 act as a potential oncogene in pancreatic cancer progression. Co-author DOI 10.1016/j.lfs.2022.121035↗
  5. Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling. Co-author DOI 10.1038/s41419-022-05082-3↗
  6. Correction: Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling. Co-author DOI 10.1038/s41419-022-05236-3↗
  7. Autophagic Schwann cells promote perineural invasion mediated by the NGF/ATG7 paracrine pathway in pancreatic cancer. Co-author DOI 10.1186/s13046-021-02198-w↗
  8. Huaier suppresses pancreatic cancer progression via activating cell autophagy induced ferroptosis. Co-author DOI 10.3389/fonc.2022.960858↗
  9. RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/ijbs.72204↗
  10. Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling. Co-author DOI 10.3389/fonc.2021.728583↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Weikun Qian · 8 shared papers, 2022–2026 · strength 1.31
  2. Wunai Zhang · 8 shared papers, 2021–2026 · strength 1.28
  3. Qingyong Ma · 8 shared papers, 2021–2025 · strength 1.18
  4. Simei Zhang · 7 shared papers, 2021–2026 · strength 1.06
  5. Zheng Wu · 6 shared papers, 2022–2025 · strength 0.92
  6. Zheng Wang · 5 shared papers, 2022–2026 · strength 0.82
  7. Weifan Zhang · 5 shared papers, 2022 · strength 0.70
  8. Yangyang Yue · 3 shared papers, 2022–2026 · strength 0.52
  9. Tao Qin · 2 shared papers, 2021–2026 · strength 0.36
  10. Shuai Wu · 2 shared papers, 2022–2025 · strength 0.35
  11. Cancan Zhou · 2 shared papers, 2022–2025 · strength 0.35
  12. Jiantao Mo · 2 shared papers, 2022 · strength 0.28
  13. Bo Zhang · 2 shared papers, 2022 · strength 0.28
  14. Li Li · 2 shared papers, 2022 · strength 0.27
  15. Zheng Wang · 2 shared papers, 2021–2022 · strength 0.25
  16. Yiqun Song · 1 shared paper, 2026 · strength 0.25
  17. Liang Han · 2 shared papers, 2021–2022 · strength 0.24
  18. Jie Hao · 1 shared paper, 2025 · strength 0.22
  19. Ruiqi Cao · 1 shared paper, 2025 · strength 0.22
  20. Xuqi Li · 1 shared paper, 2025 · strength 0.22
  21. Xin Chen · 1 shared paper, 2022 · strength 0.15
  22. Zheng Wu · 1 shared paper, 2022 · strength 0.14
  23. Keping Xie · 1 shared paper, 2022 · strength 0.14
  24. Wenbin Yang · 1 shared paper, 2022 · strength 0.13
  25. Junhui Li · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.